NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
TORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (“NurExone” or the “Company“) (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced new preclinical tissue-analysis results that provide additional biological support for ExoPTEN’s potential neuroprotective effect in an animal model
August 14, 2026